|
1
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Filipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: Are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hobert O: Gene regulation by transcription
factors and microRNAs. Science. 319:1785–1786. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Iorio MV and Croce CM: MicroRNAs in
cancer: Small molecules with a huge impact. J Clin Oncol.
27:5848–5856. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rolfo C, Fanale D, Hong DS, Tsimberidou
AM, Piha-Paul SA, Pauwels P, Van Meerbeeck JP, Caruso S, Bazan V,
Cicero G, et al: Impact of microRNAs in resistance to chemotherapy
and novel targeted agents in non-small cell lung cancer. Curr Pharm
Biotechnol. 15:475–485. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yanaihara N, Caplen N, Bowman E, Seike M,
Kumamoto K, Yi M, Stephens RM, Okamoto A, Yokota J, Tanaka T, et
al: Unique microRNA molecular profiles in lung cancer diagnosis and
prognosis. Cancer Cell. 9:189–198. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Raponi M, Dossey L, Jatkoe T, Wu X, Chen
G, Fan H and Beer DG: MicroRNA classifiers for predicting prognosis
of squamous cell lung cancer. Cancer Res. 69:5776–5783. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Moriya Y, Nohata N, Kinoshita T, Mutallip
M, Okamoto T, Yoshida S, Suzuki M, Yoshino I and Seki N: Tumor
suppressive microRNA-133a regulates novel molecular networks in
lung squamous cell carcinoma. J Hum Genet. 57:38–45. 2012.
View Article : Google Scholar
|
|
9
|
Mataki H, Enokida H, Chiyomaru T, Mizuno
K, Matsushita R, Goto Y, Nishikawa R, Higashimoto I, Samukawa T,
Nakagawa M, et al: Downregulation of the microRNA-1/133a cluster
enhances cancer cell migration and invasion in lung-squamous cell
carcinoma via regulation of Coronin1C. J Hum Genet. 60:53–61. 2015.
View Article : Google Scholar
|
|
10
|
Mataki H, Seki N, Chiyomaru T, Enokida H,
Goto Y, Kumamoto T, Machida K, Mizuno K, Nakagawa M and Inoue H:
Tumor-suppressive microRNA-206 as a dual inhibitor of MET and EGFR
oncogenic signaling in lung squamous cell carcinoma. Int J Oncol.
46:1039–1050. 2015.
|
|
11
|
Mizuno K, Seki N, Mataki H, Matsushita R,
Kamikawaji K, Kumamoto T, Takagi K, Goto Y, Nishikawa R, Kato M, et
al: Tumor-suppressive microRNA-29 family inhibits cancer cell
migration and invasion directly targeting LOXL2 in lung squamous
cell carcinoma. Int J Oncol. 48:450–460. 2016.
|
|
12
|
Kikkawa N, Hanazawa T, Fujimura L, Nohata
N, Suzuki H, Chazono H, Sakurai D, Horiguchi S, Okamoto Y and Seki
N: miR-489 is a tumour-suppressive miRNA target PTPN11 in
hypopharyngeal squamous cell carcinoma (HSCC). Br J Cancer.
103:877–884. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hidaka H, Seki N, Yoshino H, Yamasaki T,
Yamada Y, Nohata N, Fuse M, Nakagawa M and Enokida H: Tumor
suppressive microRNA-1285 regulates novel molecular targets:
Aberrant expression and functional significance in renal cell
carcinoma. Oncotarget. 3:44–57. 2012.PubMed/NCBI
|
|
14
|
Itesako T, Seki N, Yoshino H, Chiyomaru T,
Yamasaki T, Hidaka H, Yonezawa T, Nohata N, Kinoshita T, Nakagawa
M, et al: The microRNA expression signature of bladder cancer by
deep sequencing: The functional significance of the miR-195/497
cluster. PLoS One. 9:e843112014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kojima S, Enokida H, Yoshino H, Itesako T,
Chiyomaru T, Kinoshita T, Fuse M, Nishikawa R, Goto Y, Naya Y, et
al: The tumor-suppressive microRNA-143/145 cluster inhibits cell
migration and invasion by targeting GOLM1 in prostate cancer. J Hum
Genet. 59:78–87. 2014. View Article : Google Scholar
|
|
16
|
Tatarano S, Chiyomaru T, Kawakami K,
Enokida H, Yoshino H, Hidaka H, Yamasaki T, Kawahara K, Nishiyama
K, Seki N, et al: miR-218 on the genomic loss region of chromosome
4p15.31 functions as a tumor suppressor in bladder cancer. Int J
Oncol. 39:13–21. 2011.PubMed/NCBI
|
|
17
|
Kinoshita T, Hanazawa T, Nohata N, Kikkawa
N, Enokida H, Yoshino H, Yamasaki T, Hidaka H, Nakagawa M, Okamoto
Y, et al: Tumor suppressive microRNA-218 inhibits cancer cell
migration and invasion through targeting laminin-332 in head and
neck squamous cell carcinoma. Oncotarget. 3:1386–1400. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yamamoto N, Kinoshita T, Nohata N, Itesako
T, Yoshino H, Enokida H, Nakagawa M, Shozu M and Seki N: Tumor
suppressive microRNA-218 inhibits cancer cell migration and
invasion by targeting focal adhesion pathways in cervical squamous
cell carcinoma. Int J Oncol. 42:1523–1532. 2013.PubMed/NCBI
|
|
19
|
Goldstraw P, Crowley J, Chansky K, Giroux
DJ, Groome PA, Rami-Porta R, Postmus PE, Rusch V and Sobin L;
International Association for the Study of Lung Cancer
International Staging Committee; Participating Institutions. The
IASLC Lung Cancer Staging Project: Proposals for the revision of
the TNM stage groupings in the forthcoming (seventh) edition of the
TNM Classification of malignant tumours. J Thorac Oncol. 2:706–714.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fukumoto I, Kinoshita T, Hanazawa T,
Kikkawa N, Chiyomaru T, Enokida H, Yamamoto N, Goto Y, Nishikawa R,
Nakagawa M, et al: Identification of tumour suppressive
microRNA-451a in hypopharyngeal squamous cell carcinoma based on
microRNA expression signature. Br J Cancer. 111:386–394. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Matsushita R, Seki N, Chiyomaru T,
Inoguchi S, Ishihara T, Goto Y, Nishikawa R, Mataki H, Tatarano S,
Itesako T, et al: Tumour-suppressive microRNA-144-5p directly
targets CCNE1/2 as potential prognostic markers in bladder cancer.
Br J Cancer. 113:282–289. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lu YF, Zhang L, Waye MM, Fu WM and Zhang
JF: MiR-218 mediates tumorigenesis and metastasis: Perspectives and
implications. Exp Cell Res. 334:173–182. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yamasaki T, Seki N, Yoshino H, Itesako T,
Hidaka H, Yamada Y, Tatarano S, Yonezawa T, Kinoshita T, Nakagawa
M, et al: MicroRNA-218 inhibits cell migration and invasion in
renal cell carcinoma through targeting caveolin-2 involved in focal
adhesion pathway. J Urol. 190:1059–1068. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Nishikawa R, Goto Y, Sakamoto S, Chiyomaru
T, Enokida H, Kojima S, Kinoshita T, Yamamoto N, Nakagawa M, Naya
Y, et al: Tumor-suppressive microRNA-218 inhibits cancer cell
migration and invasion via targeting of LASP1 in prostate cancer.
Cancer Sci. 105:802–811. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Weaver VM, Petersen OW, Wang F, Larabell
CA, Briand P, Damsky C and Bissell MJ: Reversion of the malignant
phenotype of human breast cells in three-dimensional culture and in
vivo by integrin blocking antibodies. J Cell Biol. 137:231–245.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bissell MJ and Radisky D: Putting tumours
in context. Nat Rev Cancer. 1:46–54. 2001. View Article : Google Scholar
|
|
27
|
Hood JD and Cheresh DA: Role of integrins
in cell invasion and migration. Nat Rev Cancer. 2:91–100. 2002.
View Article : Google Scholar
|
|
28
|
Fukumoto I, Kikkawa N, Matsushita R, Kato
M, Kurozumi A, Nishikawa R, Goto Y, Koshizuka K, Hanazawa T,
Enokida H, et al: Tumor-suppressive microRNAs (miR-26a/b,
miR-29a/b/c and miR-218) concertedly suppressed
metastasis-promoting LOXL2 in head and neck squamous cell
carcinoma. J Hum Genet. 61:109–118. 2016. View Article : Google Scholar
|
|
29
|
Kogo R, How C, Chaudary N, Bruce J, Shi W,
Hill RP, Zahedi P, Yip KW and Liu FF: The microRNA-218~Survivin
axis regulates migration, invasion, and lymph node metastasis in
cervical cancer. Oncotarget. 6:1090–1100. 2015. View Article : Google Scholar :
|
|
30
|
Byrne JA, Tomasetto C, Garnier JM, Rouyer
N, Mattei MG, Bellocq JP, Rio MC and Basset P: A screening method
to identify genes commonly overexpressed in carcinomas and the
identification of a novel complementary DNA sequence. Cancer Res.
55:2896–2903. 1995.PubMed/NCBI
|
|
31
|
Byrne JA, Balleine RL, Schoenberg Fejzo M,
Mercieca J, Chiew YE, Livnat Y, St Heaps L, Peters GB, Byth K,
Karlan BY, et al: Tumor protein D52 (TPD52) is overexpressed and a
gene amplification target in ovarian cancer. Int J Cancer.
117:1049–1054. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Rubin MA, Varambally S, Beroukhim R,
Tomlins SA, Rhodes DR, Paris PL, Hofer MD, Storz-Schweizer M,
Kuefer R, Fletcher JA, et al: Overexpression, amplification, and
androgen regulation of TPD52 in prostate cancer. Cancer Res.
64:3814–3822. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Roslan N, Bièche I, Bright RK, Lidereau R,
Chen Y and Byrne JA: TPD52 represents a survival factor in
ERBB2-amplified breast cancer cells. Mol Carcinog. 53:807–819.
2014. View Article : Google Scholar
|
|
34
|
Weir BA, Woo MS, Getz G, Perner S, Ding L,
Beroukhim R, Lin WM, Province MA, Kraja A, Johnson LA, et al:
Characterizing the cancer genome in lung adenocarcinoma. Nature.
450:893–898. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rohrbeck A, Neukirchen J, Rosskopf M,
Pardillos GG, Geddert H, Schwalen A, Gabbert HE, von Haeseler A,
Pitschke G, Schott M, et al: Gene expression profiling for
molecular distinction and characterization of laser captured
primary lung cancers. J Transl Med. 6:692008. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhu H, Lam DC, Han KC, Tin VP, Suen WS,
Wang E, Lam WK, Cai WW, Chung LP and Wong MP: High resolution
analysis of genomic aberrations by metaphase and array comparative
genomic hybridization identifies candidate tumour genes in lung
cancer cell lines. Cancer Lett. 245:303–314. 2007. View Article : Google Scholar
|
|
37
|
Hanada S, Kakehashi A, Nishiyama N, Wei M,
Yamano S, Chung K, Komatsu H, Inoue H, Suehiro S and Wanibuchi H:
Myristoylated alanine-rich C-kinase substrate as a prognostic
biomarker in human primary lung squamous cell carcinoma. Cancer
Biomark. 13:289–298. 2013.PubMed/NCBI
|
|
38
|
Boelens MC, van den Berg A, Fehrmann RS,
Geerlings M, de Jong WK, te Meerman GJ, Sietsma H, Timens W, Postma
DS and Groen HJ: Current smoking-specific gene expression signature
in normal bronchial epithelium is enhanced in squamous cell lung
cancer. J Pathol. 218:182–191. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Lewis JD, Payton LA, Whitford JG, Byrne
JA, Smith DI, Yang L and Bright RK: Induction of tumorigenesis and
metastasis by the murine orthologue of tumor protein D52. Mol
Cancer Res. 5:133–144. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ummanni R, Teller S, Junker H, Zimmermann
U, Venz S, Scharf C, Giebel J and Walther R: Altered expression of
tumor protein D52 regulates apoptosis and migration of prostate
cancer cells. FEBS J. 275:5703–5713. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Li L, Xie H, Liang L, Gao Y, Zhang D, Fang
L, Lee SO, Luo J, Chen X, Wang X, et al: Increased PrLZ-mediated
androgen receptor transactivation promotes prostate cancer growth
at castration-resistant stage. Carcinogenesis. 34:257–267. 2013.
View Article : Google Scholar :
|
|
42
|
Takahashi Y, Forrest AR, Maeno E,
Hashimoto T, Daub CO and Yasuda J: MiR-107 and MiR-185 can induce
cell cycle arrest in human non small cell lung cancer cell lines.
PLoS One. 4:e66772009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kaller M, Liffers ST, Oeljeklaus S,
Kuhlmann K, Röh S, Hoffmann R, Warscheid B and Hermeking H:
Genome-wide characterization of miR-34a induced changes in protein
and mRNA expression by a combined pulsed SILAC and microarray
analysis. Mol Cell Proteomics. 10:M111 010462. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Goto Y, Nishikawa R, Kojima S, Chiyomaru
T, Enokida H, Inoguchi S, Kinoshita T, Fuse M, Sakamoto S, Nakagawa
M, et al: Tumour-suppressive microRNA-224 inhibits cancer cell
migration and invasion via targeting oncogenic TPD52 in prostate
cancer. FEBS Lett. 588:1973–1982. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Han G, Fan M and Zhang X: microRNA-218
inhibits prostate cancer cell growth and promotes apoptosis by
repressing TPD52 expression. Biochem Biophys Res Commun.
456:804–809. 2015. View Article : Google Scholar
|
|
46
|
Aarts M, Linardopoulos S and Turner NC:
Tumour selective targeting of cell cycle kinases for cancer
treatment. Curr Opin Pharmacol. 13:529–535. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dominguez-Brauer C, Thu KL, Mason JM,
Blaser H, Bray MR and Mak TW: Targeting mitosis in cancer: Emerging
strategies. Mol Cell. 60:524–536. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Liu X, Liao W, Yuan Q, Ou Y and Huang J:
TTK activates Akt and promotes proliferation and migration of
hepatocellular carcinoma cells. Oncotarget. 6:34309–34320.
2015.PubMed/NCBI
|
|
49
|
Nyati S, Schinske-Sebolt K, Pitchiaya S,
Chekhovskiy K, Chator A, Chaudhry N, Dosch J, Van Dort ME,
Varambally S, Kumar-Sinha C, et al: The kinase activity of the
Ser/Thr kinase BUB1 promotes TGF-β signaling. Sci Signal.
8:ra12015. View Article : Google Scholar
|
|
50
|
Wu J, Ivanov AI, Fisher PB and Fu Z:
Polo-like kinase 1 induces epithelial-to-mesenchymal transition and
promotes epithelial cell motility by activating CRAF/ERK signaling.
eLife. 5:52016. View Article : Google Scholar
|
|
51
|
Lei CY, Wang W, Zhu YT, Fang WY and Tan
WL: The decrease of cyclin B2 expression inhibits invasion and
metastasis of bladder cancer. Urol Oncol. 34:237.e1–237.e10. 2016.
View Article : Google Scholar
|
